drugset
drugset / Trial / NCT02182232

A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

NCT02182232 ↗

Phase 1 Completed 33 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment

Timeline

Start
2005-06
Primary completion
2007-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule — Oral
Background Carboplatin Small molecule — —
Background Paclitaxel Small molecule — —

Indications

non-small cell lung carcinoma